Login / Signup

Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.

Reshma L MahtaniAlexander NiyazovKatie LewisAlex RiderLucy MasseyBhakti ArondekarMichael P Lux
Published in: Advances in therapy (2022)
Testing and genetic counseling rates for BRCA1/2 mutations were very high in Israel, potentially due to the high rate of family history of BRCA-related cancer in this population and higher general awareness of genetic testing. In the EU4 and USA, overall rates of testing for BRCA1/2 mutations and genetic counseling were significantly lower compared with Israel. Given the high risk of breast cancer in BRCA1/2 mutation carriers and the efficacy of new therapies in treating ABC with a BRCA1/2 mutation, efforts should be made to improve BRCA1/2 testing rates in Europe and the USA.
Keyphrases
  • breast cancer risk
  • epidermal growth factor receptor
  • endothelial cells
  • squamous cell carcinoma
  • gene expression
  • case report
  • young adults
  • human immunodeficiency virus
  • hepatitis c virus
  • lymph node metastasis